DD266027A5 - Arzneimittelhaltige fasern mit geregelter freisetzung - Google Patents

Arzneimittelhaltige fasern mit geregelter freisetzung Download PDF

Info

Publication number: DD266027A5
Authority: DD; German Democratic Republic
Prior art keywords: fiber; drug; fibers; polymer; item
Prior art date: 1986-07-15

Application number

DD87304939A

Other languages

German (de)

English (en)

Inventor

William J Curatolo

Original Assignee

��@��Kk��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-15

Filing date

1987-07-14

Publication date

1989-03-22

1987-07-14 Application filed by ��@��Kk�� filed Critical ��@��Kk��

1989-03-22 Publication of DD266027A5 publication Critical patent/DD266027A5/de

Links

239000000835 fiber Substances 0.000 title claims abstract description 266
230000001105 regulatory effect Effects 0.000 title description 2
239000003814 drug Substances 0.000 claims abstract description 114
229940079593 drug Drugs 0.000 claims abstract description 112
210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 25
238000013270 controlled release Methods 0.000 claims abstract description 18
230000014759 maintenance of location Effects 0.000 claims description 65
229920000642 polymer Polymers 0.000 claims description 33
238000000034 method Methods 0.000 claims description 17
239000007788 liquid Substances 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 6
239000000725 suspension Substances 0.000 claims description 5
239000012530 fluid Substances 0.000 claims description 4
238000006116 polymerization reaction Methods 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 3
239000000376 reactant Substances 0.000 claims description 3
229920013641 bioerodible polymer Polymers 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
238000001816 cooling Methods 0.000 claims 1
239000002657 fibrous material Substances 0.000 claims 1
229920002959 polymer blend Polymers 0.000 claims 1
239000002861 polymer material Substances 0.000 claims 1
241000124008 Mammalia Species 0.000 abstract description 5
210000002784 stomach Anatomy 0.000 description 55
230000002496 gastric effect Effects 0.000 description 45
239000003826 tablet Substances 0.000 description 37
241000282472 Canis lupus familiaris Species 0.000 description 36
230000000717 retained effect Effects 0.000 description 22
239000000463 material Substances 0.000 description 21
241000700159 Rattus Species 0.000 description 20
229920000728 polyester Polymers 0.000 description 20
239000000203 mixture Substances 0.000 description 15
239000005038 ethylene vinyl acetate Substances 0.000 description 14
239000002552 dosage form Substances 0.000 description 13
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 13
229920000260 silastic Polymers 0.000 description 13
210000000813 small intestine Anatomy 0.000 description 13
241001465754 Metazoa Species 0.000 description 11
239000011324 bead Substances 0.000 description 10
239000002775 capsule Substances 0.000 description 10
229960001389 doxazosin Drugs 0.000 description 10
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 10
238000009472 formulation Methods 0.000 description 10
-1 that is Polymers 0.000 description 10
238000010521 absorption reaction Methods 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000004698 Polyethylene Substances 0.000 description 7
229920000573 polyethylene Polymers 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 6
239000013305 flexible fiber Substances 0.000 description 6
235000013305 food Nutrition 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000003204 osmotic effect Effects 0.000 description 5
239000008188 pellet Substances 0.000 description 5
238000002601 radiography Methods 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
230000008030 elimination Effects 0.000 description 4
238000003379 elimination reaction Methods 0.000 description 4
239000007948 fast release tablet Substances 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
210000002438 upper gastrointestinal tract Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
229920002301 cellulose acetate Polymers 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
239000002131 composite material Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000037213 diet Effects 0.000 description 3
229960000220 doxazosin mesylate Drugs 0.000 description 3
VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000004051 gastric juice Anatomy 0.000 description 3
238000003304 gavage Methods 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
210000002445 nipple Anatomy 0.000 description 3
210000001187 pylorus Anatomy 0.000 description 3
239000001993 wax Substances 0.000 description 3
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000036765 blood level Effects 0.000 description 2
235000021152 breakfast Nutrition 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
238000000576 coating method Methods 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
210000001198 duodenum Anatomy 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
239000012510 hollow fiber Substances 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
238000007455 ileostomy Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000003183 myoelectrical effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
238000010998 test method Methods 0.000 description 2
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
LWNPNOFGINFGGV-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;2-(dimethylamino)ethyl 4-(butylamino)benzoate Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 LWNPNOFGINFGGV-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
229920002284 Cellulose triacetate Polymers 0.000 description 1
235000010919 Copernicia prunifera Nutrition 0.000 description 1
244000180278 Copernicia prunifera Species 0.000 description 1
IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010022355 Fibroins Proteins 0.000 description 1
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
239000004100 Oxytetracycline Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004642 Polyimide Substances 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
241000282849 Ruminantia Species 0.000 description 1
SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
241000270295 Serpentes Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
IIOPVJIGEATDBS-UHFFFAOYSA-N acetic acid;dodecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCC(O)=O IIOPVJIGEATDBS-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910001964 alkaline earth metal nitrate Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
238000005452 bending Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000004566 building material Substances 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
238000005253 cladding Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000000806 elastomer Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229960002690 fluphenazine Drugs 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
229960002867 griseofulvin Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
210000003767 ileocecal valve Anatomy 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000004200 microcrystalline wax Substances 0.000 description 1
235000019808 microcrystalline wax Nutrition 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
229920001558 organosilicon polymer Polymers 0.000 description 1
229960000625 oxytetracycline Drugs 0.000 description 1
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
235000019366 oxytetracycline Nutrition 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229960005414 pirbuterol Drugs 0.000 description 1
239000010773 plant oil Substances 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
229920001721 polyimide Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical class [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
229960000581 salicylamide Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
238000004088 simulation Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000009182 swimming Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229920002725 thermoplastic elastomer Polymers 0.000 description 1
229960003279 thiopental Drugs 0.000 description 1
229960004214 tioconazole Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
235000019156 vitamin B Nutrition 0.000 description 1
239000011720 vitamin B Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
238000003466 welding Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nanotechnology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DD87304939A 1986-07-15 1987-07-14 Arzneimittelhaltige fasern mit geregelter freisetzung DD266027A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US88597586A	1986-07-15	1986-07-15

Publications (1)

Publication Number	Publication Date
DD266027A5 true DD266027A5 (de)	1989-03-22

Family

ID=25388112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD87304939A DD266027A5 (de)	1986-07-15	1987-07-14	Arzneimittelhaltige fasern mit geregelter freisetzung

Country Status (18)

Country	Link
EP (1)	EP0253554A3 (fr)
JP (1)	JPS6323815A (fr)
KR (1)	KR900000512B1 (fr)
CN (1)	CN87104918A (fr)
AU (1)	AU574955B2 (fr)
CA (1)	CA1296632C (fr)
DD (1)	DD266027A5 (fr)
DK (1)	DK364987A (fr)
FI (1)	FI873114L (fr)
HU (1)	HUT45195A (fr)
IL (1)	IL83136A0 (fr)
NO (1)	NO872924L (fr)
NZ (1)	NZ221071A (fr)
PH (1)	PH24299A (fr)
PL (1)	PL266839A1 (fr)
PT (1)	PT85315B (fr)
YU (1)	YU46903B (fr)
ZA (1)	ZA875125B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4837111A (en) *	1988-03-21	1989-06-06	Alza Corporation	Dosage form for dispensing drug for human therapy
US5198251A (en) *	1989-04-19	1993-03-30	Wm. Wrigley Jr. Company	Gradual release structures for chewing gum
US5154939A (en) *	1989-04-19	1992-10-13	Wm. Wrigley Jr. Company	Use of salt to improve extrusion encapsulation of chewing gum ingredients
US5108762A (en) *	1989-04-19	1992-04-28	Wm. Wrigley Jr. Company	Gradual release structures for chewing gum
US5229148A (en) *	1989-04-19	1993-07-20	Wm. Wrigley Jr. Company	Method of combining active ingredients with polyvinyl acetates
FI904598A7 (fi) *	1989-10-10	1991-04-11	Wrigley W M Jun Co	Kuidunkehruutekniikalla valmistetut ainetta vähitellen vapauttavat rakenteet
AU7991191A (en) *	1990-05-23	1991-12-10	Southwest Research Institute	Filament system for delivering a medicament and method
NZ245076A (en) *	1992-10-07	1994-09-27	William Leslie Porter	Animal feed supplement comprising an at least partly oxidised alloy of copper in combination with at least one other trace element
US5538735A (en) *	1993-02-19	1996-07-23	Ahn; Sam S.	Method of making a drug delivery system using hollow fibers
US5482718A (en) *	1994-03-23	1996-01-09	Hoffmann-La Roche Inc.	Colon-targeted delivery system
EP0849265A1 (fr) *	1996-12-20	1998-06-24	HEUMANN PHARMA GmbH	Nouvelle forme polymorphique de mésylate de doxazosin (forme II)
WO2000050349A2 (fr) *	1999-02-22	2000-08-31	Bioxid Oy	Fibres ceramiques biodegradables provenant de sols siliceux
US6488962B1 (en) *	2000-06-20	2002-12-03	Depomed, Inc.	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20040249364A1 (en) *	2003-06-03	2004-12-09	Ilya Kaploun	Device and method for dispensing medication to tissue lining a body cavity
US20050002996A1 (en) *	2003-07-02	2005-01-06	Milan Sojka	Sustained release compositions and controlled delivery method
IN2014DN11097A (fr) *	2012-06-04	2015-09-25	Migrata U K Ltd
NZ727659A (en) *	2014-06-11	2021-12-24	Massachusetts Inst Technology	Residence structures and related methods
US11576859B2 (en)	2015-10-23	2023-02-14	Lyndra Therapeutics, Inc.	Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
EP3368010B1 (fr) *	2015-10-26	2025-12-10	Blaesi, Aron H.	Forme galénique solide à libération immédiate de médicament et appareil et procédé de fabrication associés
WO2017100367A1 (fr)	2015-12-08	2017-06-15	Lyndra, Inc.	Configurations géométriques de systèmes à résidence gastrique
CN109310639A (zh)	2016-05-27	2019-02-05	林德拉有限公司	用于胃驻留系统的材料结构
JP2019532947A (ja)	2016-09-30	2019-11-14	リンドラ，インコーポレイティド	アダマンタン系薬物の持続的送達のための胃内滞留システム
CA3066658A1 (fr)	2017-06-09	2018-12-13	Lyndra, Inc.	Systemes gastriques a demeure avec films modulant le taux de liberation
WO2022072735A1 (fr) *	2020-09-30	2022-04-07	Blaesi Aron H	Forme posologique structurée à rétention gastrique
HUE067496T2 (hu)	2020-12-08	2024-10-28	Ruminant Biotech Corp Ltd	Az állatoknak szánt anyagok bejuttatására szolgáló eszközök és módszerek fejlesztése

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8401912A (nl) *	1984-06-15	1986-01-02	Tno	Met aktieve stof beladen biodegradeerbare polymeersubstraten, geschikt voor het gecontroleerd afgeven van de aktieve stof door middel van een membraan.
US4673565A (en) *	1985-05-03	1987-06-16	E. I. Du Pont De Nemours And Company	Pharmaceutical compositions containing hollow fine tubular drug delivery systems

1987
- 1987-07-07 EP EP87305979A patent/EP0253554A3/fr not_active Withdrawn
- 1987-07-09 IL IL83136A patent/IL83136A0/xx unknown
- 1987-07-12 YU YU130287A patent/YU46903B/sh unknown
- 1987-07-13 PT PT85315A patent/PT85315B/pt not_active IP Right Cessation
- 1987-07-13 CA CA000541904A patent/CA1296632C/fr not_active Expired - Lifetime
- 1987-07-14 AU AU75626/87A patent/AU574955B2/en not_active Ceased
- 1987-07-14 DD DD87304939A patent/DD266027A5/de not_active IP Right Cessation
- 1987-07-14 DK DK364987A patent/DK364987A/da not_active Application Discontinuation
- 1987-07-14 NO NO872924A patent/NO872924L/no unknown
- 1987-07-14 HU HU873214A patent/HUT45195A/hu unknown
- 1987-07-14 CN CN198787104918A patent/CN87104918A/zh active Pending
- 1987-07-14 ZA ZA875125A patent/ZA875125B/xx unknown
- 1987-07-14 KR KR1019870007531A patent/KR900000512B1/ko not_active Expired
- 1987-07-14 NZ NZ221071A patent/NZ221071A/xx unknown
- 1987-07-14 FI FI873114A patent/FI873114L/fi not_active Application Discontinuation
- 1987-07-15 PL PL1987266839A patent/PL266839A1/xx unknown
- 1987-07-15 PH PH35541A patent/PH24299A/en unknown
- 1987-07-15 JP JP62176925A patent/JPS6323815A/ja active Pending

Also Published As

Publication number	Publication date
KR880001280A (ko)	1988-04-22
KR900000512B1 (ko)	1990-01-31
ZA875125B (en)	1988-03-30
NO872924D0 (no)	1987-07-14
AU574955B2 (en)	1988-07-14
YU46903B (sh)	1994-06-24
FI873114A0 (fi)	1987-07-14
PH24299A (en)	1990-05-29
FI873114A7 (fi)	1988-01-16
CN87104918A (zh)	1988-01-27
NO872924L (no)	1988-01-18
CA1296632C (fr)	1992-03-03
FI873114L (fi)	1988-01-16
NZ221071A (en)	1990-03-27
DK364987A (da)	1988-01-16
EP0253554A2 (fr)	1988-01-20
PT85315B (pt)	1990-04-30
JPS6323815A (ja)	1988-02-01
DK364987D0 (da)	1987-07-14
IL83136A0 (en)	1987-12-31
PL266839A1 (en)	1988-07-21
YU130287A (en)	1988-10-31
AU7562687A (en)	1988-01-21
PT85315A (en)	1987-08-01
EP0253554A3 (fr)	1988-07-20
HUT45195A (en)	1988-06-28

Legal Events

Date	Code	Title	Description
1994-04-14	NPV	Change in the person, the name or the address of the representative (addendum to changes before extension act)
1995-02-02	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD266027A5 (de)	1989-03-22	Arzneimittelhaltige fasern mit geregelter freisetzung
DE68904596T2 (de)	1993-05-19	Gastrisches zurueckhaltungssystem zur kontrollierten arzneiabgabe.
DE69427664T2 (de)	2001-10-25	PH-induzierte durch Osmose zerplatzende Abgabevorrichtungen
DE69011878T2 (de)	1994-12-15	Von Hydrogel angetriebene Verabreichungsvorrichtung.
DE69212710T2 (de)	1996-12-19	Pharmazeutische Zusammensetzung mit kontrollierter Freigabe und bioadhäsiven Eigenschaften
DE69629797T2 (de)	2004-07-15	Matrix zur gesteuerten freisetzung von arzneistoffen
DE69927708T2 (de)	2006-07-06	Dosierungsformen, die poröse partikel enthalten
DE69432618T2 (de)	2004-02-19	Arzneimittel mit gesteuertem Beginn und gesteuerter Rate der Freisetzung
DE69208299T2 (de)	1996-07-18	Feste Arzneizubereitungen zur oralen Verabreichung mit verlängerter Magenverweilzeit
DE69524214T2 (de)	2002-05-23	Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
DE69909801T2 (de)	2004-06-03	Oral verabreichtes system zur zeitlich und räumlich gesteuerten arzneistoffabgabe
DE69230112T2 (de)	2000-03-02	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE69011131T2 (de)	1994-12-01	Wirkstoff enthaltende vorrichtung zur langzeitabgabe.
EP0961611B1 (fr)	2002-03-27	Systeme therapeutique gastro-retentif pouvant s'expanser, a liberation controlee de principes actifs dans le tractus gastro-intestinal
DE69325402T2 (de)	2000-02-17	Verbessertes System des Typs einmal täglich zur gepulsten Minocyclinabgabe
DE69022876T2 (de)	1996-05-02	Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe.
EP0872234B1 (fr)	2005-03-16	Forme médicale laminaire
EP0307904A1 (fr)	1989-03-22	Formes à liberation prolongée enrobées
EP0348808A2 (fr)	1990-01-03	Formulations pharmaceutiques et procédé pour leur préparation
DE102007026037A1 (de)	2008-12-11	Gastroretentives System mit Alginat-Körper
CH671696A5 (fr)	1989-09-29
DE1093050B (de)	1960-11-17	Verfahren zur Herstellung einer Penicillintablette mit verlaengerter Wirkung
DD298205A5 (de)	1992-02-13	Verfahren zum herstellen von langzeitwirkenden arzneimittelzubereitungen
DE60308828T2 (de)	2007-05-24	Orale pharmazeutische Zusammensetzung mit verzögerter Freisetzung
DE2918522C2 (de)	1986-06-19	Abgabevorrichtung zur kontrollierten und fortwährenden Zuführung einer Chemikalie während einer längeren Zeitspanne, Verwendung und Herstellverfahren dieser Vorrichtung